Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.

Flinn IW, Cherry MA, Maris MB, Matous JV, Berdeja JG, Patel M.

Am J Hematol. 2019 Dec;94(12):1325-1334. doi: 10.1002/ajh.25634. Epub 2019 Oct 4.

PMID:
31490009
2.

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, McSweeney PA, Storb R, Sorror ML.

Bone Marrow Transplant. 2019 Sep 3. doi: 10.1038/s41409-019-0660-8. [Epub ahead of print]

PMID:
31481800
3.

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.

Yalniz FF, Berdeja JG, Maris MB, Lyons RM, Reeves JA Jr, Essell JH, Patel P, Sekeres M, Hughes A, Mappa S, Garcia-Manero G.

Br J Haematol. 2019 Aug 29. doi: 10.1111/bjh.16173. [Epub ahead of print]

PMID:
31468521
4.

Are Inherited Combined Thrombophilia Mutations a Causative or an Additive Factor in Recurrent Venous Thrombotic Accidents?

Maris MI, Cadariu FG, Avram MF, Parv F, Rogobete AF, Muntean DM, Borza C.

Clin Lab. 2019 Jul 1;65(7). doi: 10.7754/Clin.Lab.2019.181221.

PMID:
31307155
5.

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.

Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R.

Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24.

PMID:
31248843
6.

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study.

Van Gaal L, Hermans MP, Daci E, Denhaerynck K, De Meester L, MacDonald K, Abraham I, Vancayzeele S, Maris M.

Diabetes Ther. 2019 Jun;10(3):965-979. doi: 10.1007/s13300-019-0601-y. Epub 2019 Mar 27.

7.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

8.

The Mechanical Contribution of Vimentin to Cellular Stress Generation.

van Loosdregt IAEW, Weissenberger G, van Maris MPFHL, Oomens CWJ, Loerakker S, Stassen OMJA, Bouten CVC.

J Biomech Eng. 2018 Jun 1;140(6). doi: 10.1115/1.4039308.

PMID:
29450503
9.

From Fibrils to Toughness: Multi-Scale Mechanics of Fibrillating Interfaces in Stretchable Electronics.

van der Sluis O, Vermeij T, Neggers J, Vossen B, van Maris M, Vanfleteren J, Geers M, Hoefnagels J.

Materials (Basel). 2018 Feb 2;11(2). pii: E231. doi: 10.3390/ma11020231.

10.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR.

Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.

11.

Effects of matrix on plasma levels of EPA and DHA in dogs.

Goffin K, van Maris M, Corbee RJ.

J Nutr Sci. 2017 Jul 24;6:e37. doi: 10.1017/jns.2017.30. eCollection 2017.

12.

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ.

Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1. No abstract available.

13.

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.

Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ.

Cancer. 2017 May 15;123(6):994-1002. doi: 10.1002/cncr.30533. Epub 2017 Jan 17.

14.

Drug-induced sedation endoscopy in surgically naive children with Down syndrome and obstructive sleep apnea.

Maris M, Verhulst S, Saldien V, Van de Heyning P, Wojciechowski M, Boudewyns A.

Sleep Med. 2016 Aug;24:63-70. doi: 10.1016/j.sleep.2016.06.018. Epub 2016 Aug 22.

PMID:
27810188
15.

Outcome of adenotonsillectomy in children with Down syndrome and obstructive sleep apnoea.

Maris M, Verhulst S, Wojciechowski M, Van de Heyning P, Boudewyns A.

Arch Dis Child. 2017 Apr;102(4):331-336. doi: 10.1136/archdischild-2015-310351. Epub 2016 Aug 2.

PMID:
27484971
16.

Sleep problems and obstructive sleep apnea in children with down syndrome, an overwiew.

Maris M, Verhulst S, Wojciechowski M, Van de Heyning P, Boudewyns A.

Int J Pediatr Otorhinolaryngol. 2016 Mar;82:12-5. doi: 10.1016/j.ijporl.2015.12.014. Epub 2016 Jan 4.

PMID:
26857307
17.

Prevalence of Obstructive Sleep Apnea in Children with Down Syndrome.

Maris M, Verhulst S, Wojciechowski M, Van de Heyning P, Boudewyns A.

Sleep. 2016 Mar 1;39(3):699-704. doi: 10.5665/sleep.5554.

18.

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG.

Cancer. 2015 Oct 15;121(20):3709-16. doi: 10.1002/cncr.29498. Epub 2015 Jul 24.

19.

Cereulide food toxin, beta cell function and diabetes: Facts and hypotheses.

Vangoitsenhoven R, Maris M, Overbergh L, Van Loco J, Mathieu C, Van der Schueren B.

Diabetes Res Clin Pract. 2015 Jul;109(1):1-5. doi: 10.1016/j.diabres.2015.04.029. Epub 2015 May 6. Review.

PMID:
25998918
20.

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.

ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, Syrjala KL, Martin PJ, Maloney DG, Sandmaier BM, Storb R, Sorror ML.

Br J Haematol. 2015 Aug;170(4):574-83. doi: 10.1111/bjh.13476. Epub 2015 May 5.

21.

Joint analysis of BICEP2/keck array and Planck Data.

Ade PA, Aghanim N, Ahmed Z, Aikin RW, Alexander KD, Arnaud M, Aumont J, Baccigalupi C, Banday AJ, Barkats D, Barreiro RB, Bartlett JG, Bartolo N, Battaner E, Benabed K, Benoît A, Benoit-Lévy A, Benton SJ, Bernard JP, Bersanelli M, Bielewicz P, Bischoff CA, Bock JJ, Bonaldi A, Bonavera L, Bond JR, Borrill J, Bouchet FR, Boulanger F, Brevik JA, Bucher M, Buder I, Bullock E, Burigana C, Butler RC, Buza V, Calabrese E, Cardoso JF, Catalano A, Challinor A, Chary RR, Chiang HC, Christensen PR, Colombo LP, Combet C, Connors J, Couchot F, Coulais A, Crill BP, Curto A, Cuttaia F, Danese L, Davies RD, Davis RJ, de Bernardis P, de Rosa A, de Zotti G, Delabrouille J, Delouis JM, Désert FX, Dickinson C, Diego JM, Dole H, Donzelli S, Doré O, Douspis M, Dowell CD, Duband L, Ducout A, Dunkley J, Dupac X, Dvorkin C, Efstathiou G, Elsner F, Enßlin TA, Eriksen HK, Falgarone E, Filippini JP, Finelli F, Fliescher S, Forni O, Frailis M, Fraisse AA, Franceschi E, Frejsel A, Galeotta S, Galli S, Ganga K, Ghosh T, Giard M, Gjerløw E, Golwala SR, González-Nuevo J, Górski KM, Gratton S, Gregorio A, Gruppuso A, Gudmundsson JE, Halpern M, Hansen FK, Hanson D, Harrison DL, Hasselfield M, Helou G, Henrot-Versillé S, Herranz D, Hildebrandt SR, Hilton GC, Hivon E, Hobson M, Holmes WA, Hovest W, Hristov VV, Huffenberger KM, Hui H, Hurier G, Irwin KD, Jaffe AH, Jaffe TR, Jewell J, Jones WC, Juvela M, Karakci A, Karkare KS, Kaufman JP, Keating BG, Kefeli S, Keihänen E, Kernasovskiy SA, Keskitalo R, Kisner TS, Kneissl R, Knoche J, Knox L, Kovac JM, Krachmalnicoff N, Kunz M, Kuo CL, Kurki-Suonio H, Lagache G, Lähteenmäki A, Lamarre JM, Lasenby A, Lattanzi M, Lawrence CR, Leitch EM, Leonardi R, Levrier F, Lewis A, Liguori M, Lilje PB, Linden-Vørnle M, López-Caniego M, Lubin PM, Lueker M, Macías-Pérez JF, Maffei B, Maino D, Mandolesi N, Mangilli A, Maris M, Martin PG, Martínez-González E, Masi S, Mason P, Matarrese S, Megerian KG, Meinhold PR, Melchiorri A, Mendes L, Mennella A, Migliaccio M, Mitra S, Miville-Deschênes MA, Moneti A, Montier L, Morgante G, Mortlock D, Moss A, Munshi D, Murphy JA, Naselsky P, Nati F, Natoli P, Netterfield CB, Nguyen HT, Nørgaard-Nielsen HU, Noviello F, Novikov D, Novikov I, O'Brient R, Ogburn RW, Orlando A, Pagano L, Pajot F, Paladini R, Paoletti D, Partridge B, Pasian F, Patanchon G, Pearson TJ, Perdereau O, Perotto L, Pettorino V, Piacentini F, Piat M, Pietrobon D, Plaszczynski S, Pointecouteau E, Polenta G, Ponthieu N, Pratt GW, Prunet S, Pryke C, Puget JL, Rachen JP, Reach WT, Rebolo R, Reinecke M, Remazeilles M, Renault C, Renzi A, Richter S, Ristorcelli I, Rocha G, Rossetti M, Roudier G, Rowan-Robinson M, Rubiño-Martín JA, Rusholme B, Sandri M, Santos D, Savelainen M, Savini G, Schwarz R, Scott D, Seiffert MD, Sheehy CD, Spencer LD, Staniszewski ZK, Stolyarov V, Sudiwala R, Sunyaev R, Sutton D, Suur-Uski AS, Sygnet JF, Tauber JA, Teply GP, Terenzi L, Thompson KL, Toffolatti L, Tolan JE, Tomasi M, Tristram M, Tucci M, Turner AD, Valenziano L, Valiviita J, Van Tent B, Vibert L, Vielva P, Vieregg AG, Villa F, Wade LA, Wandelt BD, Watson R, Weber AC, Wehus IK, White M, White SD, Willmert J, Wong CL, Yoon KW, Yvon D, Zacchei A, Zonca A; (BICEP2/Keck and Planck Collaborations).

Phys Rev Lett. 2015 Mar 13;114(10):101301. Epub 2015 Mar 9.

22.

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC.

Br J Haematol. 2015 May;169(4):534-43. doi: 10.1111/bjh.13323. Epub 2015 Mar 2. Erratum in: Br J Haematol. 2015 Oct;171(2):294. Br J Haematol. 2015 Oct;171(2):294.

23.

LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.

Li P, Oh DY, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O, Johnson A, Chung H, Maris M, Ofrecio JM, Taguchi S, Lu M, Olefsky JM.

Nat Med. 2015 Mar;21(3):239-247. doi: 10.1038/nm.3800. Epub 2015 Feb 23.

24.

FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease.

Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, Kuypers DR, Gijsbers R, Van den Haute C, Debyser Z, Baekelandt V.

Neurobiol Aging. 2015 Mar;36(3):1559-68. doi: 10.1016/j.neurobiolaging.2015.01.014. Epub 2015 Jan 21.

PMID:
25660193
25.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F.

Br J Haematol. 2015 Mar;168(6):796-805. doi: 10.1111/bjh.13214. Epub 2014 Nov 17.

26.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE.

Haematologica. 2015 Feb;100(2):231-7. doi: 10.3324/haematol.2014.114769. Epub 2014 Nov 7.

27.

Drug-induced sedation endoscopy in pediatric obstructive sleep apnea syndrome.

Boudewyns A, Verhulst S, Maris M, Saldien V, Van de Heyning P.

Sleep Med. 2014 Dec;15(12):1526-31. doi: 10.1016/j.sleep.2014.06.016. Epub 2014 Aug 27.

PMID:
25311832
28.

Knock-down of IL-1Ra in obese mice decreases liver inflammation and improves insulin sensitivity.

Franck N, Maris M, Nalbandian S, Talukdar S, Schenk S, Hofmann HP, Bullough D, Osborn O.

PLoS One. 2014 Sep 22;9(9):e107487. doi: 10.1371/journal.pone.0107487. eCollection 2014.

29.

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE.

J Clin Oncol. 2014 Oct 10;32(29):3249-56. doi: 10.1200/JCO.2013.53.8157. Epub 2014 Aug 25.

30.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.

Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM.

Haematologica. 2014 Oct;99(10):1624-31. doi: 10.3324/haematol.2014.108340. Epub 2014 Aug 1.

31.

Surface metrology and 3-dimensional confocal profiling of femtosecond laser and mechanically dissected ultrathin endothelial lamellae.

Dickman MM, van Maris MP, van Marion FW, Schuchard Y, Steijger-Vermaat P, van den Biggelaar FJ, Berendschot TT, Nuijts RM.

Invest Ophthalmol Vis Sci. 2014 Jul 29;55(8):5183-90. doi: 10.1167/iovs.14-14309.

PMID:
25074773
32.

A cross-sectional analysis of otitis media with effusion in children with Down syndrome.

Maris M, Wojciechowski M, Van de Heyning P, Boudewyns A.

Eur J Pediatr. 2014 Oct;173(10):1319-25. doi: 10.1007/s00431-014-2323-5. Epub 2014 May 10.

PMID:
24816633
33.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, Maris MB, Davis C, Deeg HJ, Lee SJ, Maloney DG, Sandmaier BM, Appelbaum FR, Gooley TA.

Blood. 2014 Jul 10;124(2):287-95. doi: 10.1182/blood-2014-01-550566. Epub 2014 May 5.

34.

Optimization of multimodal imaging of mesenchymal stem cells using the human sodium iodide symporter for PET and Cerenkov luminescence imaging.

Wolfs E, Holvoet B, Gijsbers R, Casteels C, Roberts SJ, Struys T, Maris M, Ibrahimi A, Debyser Z, Van Laere K, Verfaillie CM, Deroose CM.

PLoS One. 2014 Apr 18;9(4):e94833. doi: 10.1371/journal.pone.0094833. eCollection 2014.

35.

Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways.

Carlon MS, Vidović D, Dooley J, da Cunha MM, Maris M, Lampi Y, Toelen J, Van den Haute C, Baekelandt V, Deprest J, Verbeken E, Liston A, Gijsbers R, Debyser Z.

Hum Gene Ther. 2014 Jun;25(6):517-28. doi: 10.1089/hum.2013.196. Epub 2014 Mar 26.

36.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

37.

Specific medical and surgical treatment for chronic inflammatory diseases in children.

Boudewyns A, Antunes J, Bernheim N, Claes J, De Dooy J, De Leenheer E, De Roeck K, Hellings P, de Varebeke SJ, Jorissen M, Ketelslagers K, Lemkens N, Lemkens P, Leupe P, Malfroot A, Maris M, Michiels E, Van Crombrugge L, Vandenplas Y, Verhulst S, Eloy P, Watelet JB.

B-ENT. 2012;8 Suppl 19:135-66. Review.

PMID:
23431617
38.

Role of the saturated nonesterified fatty acid palmitate in beta cell dysfunction.

Maris M, Robert S, Waelkens E, Derua R, Hernangomez MH, D'Hertog W, Cnop M, Mathieu C, Overbergh L.

J Proteome Res. 2013 Jan 4;12(1):347-62. doi: 10.1021/pr300596g. Epub 2012 Dec 4.

PMID:
23170928
39.

An unusual tumour causing neonatal respiratory distress.

Marien A, Maris M, Verbeke S, Creytens D, Verlooy J, Van Reempts P, Boudewyns A.

B-ENT. 2012;8(2):149-51.

PMID:
22896937
40.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM.

J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14.

41.

Deletion of C/EBP homologous protein (Chop) in C57Bl/6 mice dissociates obesity from insulin resistance.

Maris M, Overbergh L, Gysemans C, Waget A, Cardozo AK, Verdrengh E, Cunha JP, Gotoh T, Cnop M, Eizirik DL, Burcelin R, Mathieu C.

Diabetologia. 2012 Apr;55(4):1167-78. doi: 10.1007/s00125-011-2427-7. Epub 2012 Jan 12.

PMID:
22237685
42.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R.

JAMA. 2011 Nov 2;306(17):1874-83. doi: 10.1001/jama.2011.1558.

43.

Oleate-induced beta cell dysfunction and apoptosis: a proteomic approach to glucolipotoxicity by an unsaturated fatty acid.

Maris M, Waelkens E, Cnop M, D'Hertog W, Cunha DA, Korf H, Koike T, Overbergh L, Mathieu C.

J Proteome Res. 2011 Aug 5;10(8):3372-85. doi: 10.1021/pr101290n. Epub 2011 Jul 13.

PMID:
21707097
44.

Auditory neuropathy/dyssynchrony as a cause of failed neonatal hearing screening.

Maris M, Venstermans C, Boudewyns AN.

Int J Pediatr Otorhinolaryngol. 2011 Jul;75(7):973-5. doi: 10.1016/j.ijporl.2011.04.012. Epub 2011 May 19.

PMID:
21596446
45.

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.

Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, Maris MB, Laport GG, Chauncey TR, Lange T, Langston AA, Storer B, Georges GE.

Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.

46.

Immunohistochemical characterisation of dendritic cells in human atherosclerotic lesions: possible pitfalls.

Van Vré EA, Bosmans JM, Van Brussel I, Maris M, De Meyer GR, Van Schil PE, Vrints CJ, Bult H.

Pathology. 2011 Apr;43(3):239-47. doi: 10.1097/PAT.0b013e328344e266.

PMID:
21436634
47.

Two-dimensional gel proteome reference map of INS-1E cells.

D'Hertog W, Maris M, Thorrez L, Waelkens E, Overbergh L, Mathieu C.

Proteomics. 2011 Apr;11(7):1365-9. doi: 10.1002/pmic.201000006. Epub 2011 Feb 17.

PMID:
21365744
48.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J.

Bone Marrow Transplant. 2012 Jan;47(1):18-23. doi: 10.1038/bmt.2011.9. Epub 2011 Feb 28.

PMID:
21358693
49.

High glucose induces dysfunction in insulin secretory cells by different pathways: a proteomic approach.

Maris M, Ferreira GB, D'Hertog W, Cnop M, Waelkens E, Overbergh L, Mathieu C.

J Proteome Res. 2010 Dec 3;9(12):6274-87. doi: 10.1021/pr100557w. Epub 2010 Nov 4.

PMID:
20942503
50.

Novel insights into the global proteome responses of insulin-producing INS-1E cells to different degrees of endoplasmic reticulum stress.

D'Hertog W, Maris M, Ferreira GB, Verdrengh E, Lage K, Hansen DA, Cardozo AK, Workman CT, Moreau Y, Eizirik DL, Waelkens E, Overbergh L, Mathieu C.

J Proteome Res. 2010 Oct 1;9(10):5142-52. doi: 10.1021/pr1004086.

PMID:
20839851

Supplemental Content

Support Center